Active	Status	Sponsor type	Region	Phase	Filter
13 Active 7 Inactive 20 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

13 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ou, Sai-Hong Ignatius
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC	Active, not recruiting	2	68	US, RoW	Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®	Effector Therapeutics, Medpace, Inc., ICON plc	Non-small Cell Lung Cancer	10/24	12/24
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination	Recruiting	1/2	576	Europe, US, RoW	MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy	Merus N.V.	Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer	03/26	03/27
NCT05394831: A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC	Recruiting	1/2	150	US, RoW	JIN-A02	J Ints Bio	EGFR Mutant Advanced Non-small Cell Lung Cancer	07/24	11/25
(MARGARET), NCT04683250: Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities	Recruiting	1/2	202	Japan, US	TAS0953/HM06	Helsinn Healthcare SA, ICON Clinical Research	RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors	03/25	09/25
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement	Recruiting	1/2	359	Europe, Canada, Japan, US, RoW	NVL-520	Nuvalent Inc., Nuvalent, Inc.	Locally Advanced Solid Tumor, Metastatic Solid Tumor	10/25	10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation	Recruiting	1/2	470	Europe, Canada, Japan, US, RoW	NVL-655	Nuvalent Inc., Nuvalent, Inc.	Locally Advanced Solid Tumor, Metastatic Solid Tumor	02/26	03/26
NCT04982224: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer	Recruiting	1/2	237	US	REGN5093-M114, Cemiplimab	Regeneron Pharmaceuticals	Advanced NSCLC	02/30	02/30
NCT04774952: Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors	Active, not recruiting	1	108	US	RMC-5552	Revolution Medicines, Inc.	Solid Tumors	03/24	03/24
Camidge, David R
BA3011-002, NCT04681131 / 2022-000135-23: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC	Active, not recruiting	2	240	Europe, US, RoW	CAB-AXL-ADC, BA3011, PD-1 inhibitor	BioAtla, Inc., BioAtla Inc.	Non-Small-Cell Lung Cancer	08/25	08/25
NCT04739358: CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC	Terminated	1/2	2	US	Tepotinib, Tepmetko	Criterium, Inc., EMD Serono Research & Development Institute, Inc.	Advanced Non-Small Cell Lung Cancer With MET Mutations	06/23	06/23
NCT05375994: Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients	Active, not recruiting	1/2	85	US	avutometinib (VS-6766) and adagrasib, KRAS G12C Inhibitor, adagrasib, KRAZATI®	Verastem, Inc., Mirati Therapeutics Inc.	Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease	12/24	01/25
BA3021-001, NCT03504488 / 2022-000137-17: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)	Completed	1/2	132	Europe, US, RoW	CAB-ROR2-ADC, BA3021, PD-1 inhibitor	BioAtla, Inc., BioAtla Inc.	Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer	12/24	12/24
NCT04982224: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer	Recruiting	1/2	237	US	REGN5093-M114, Cemiplimab	Regeneron Pharmaceuticals	Advanced NSCLC	02/30	02/30